|Day Low/High||116.48 / 118.07|
|52 Wk Low/High||73.69 / 119.84|
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
This is the kind of reversal that happens in a bull market.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
Whether this is the end of the slump is still up for debate, but the crash since October has been brutal and all bear markets end the same way.
A close below $105 for the drugmaker's shares would be bearish based on its charts.
Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
"We're all hurt someplace and we're all looking for a painkiller." -- Katherine, Looking For Mr. Goodbar As I have previously remarked there is an old trading adage that long trading opportunities often occur in stocks that are green in a sea of red...
Eli Lilly's excellent earnings weren't excellent enough.
Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
LLY's stock slide after earnings might present a buying opportunity.
A bunch of pot stocks are in play on Tuesday -- for a reason.
The giant drugmaker raised its profit guidance for all of 2018 after its third-quarter results beat expectations.
It shouldn't hurt that the drugmaker beat third-quarter estimates and raised its profit guidance for all of 2018.
Insiders buy for only one reason -- to make money.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
LLY has made a good run this year and now looks like it will correct a bit.
There is clear divergence between the best and the worst performers in each sector this earnings season.
There are concerns that interest rates may start to impact new car sales.
With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.